Researcher
Frederic Rousseau
- Disciplines (Flanders Institute for Biotechnology):Analysis of next-generation sequence data, Cell death, Behavioural neuroscience
- Disciplines (KU Leuven):Laboratory medicine, Palliative care and end-of-life care, Regenerative medicine, Other basic sciences, Other health sciences, Nursing, Other paramedical sciences, Other translational sciences, Other medical and health sciences
- See also: Frederic Rousseau (Flanders Institute for Biotechnology)
Affiliations
- Switch Laboratory (VIB-KU Leuven) (Division)
Responsible
From1 Jan 2012 → Today - Switch Lab (Research group)
Responsible
From1 Jan 2017 → Today - Switch Laboratory (VIB-KU Leuven) (Division)
Member
From1 Jan 2011 → Today - Department of Cellular and Molecular Medicine (Department)
Member
From15 Sep 2010 → 31 Dec 2010
Projects
31 - 40 of 51
- The biology of aggregation gatekeeper residuesFrom1 Jan 2017 → 31 Dec 2020Funding: FWO research project (including WEAVE projects)
- Design and development of a new vector platform for CXCR4-targeted molecular imaging and radionuclide therapyFrom1 Oct 2016 → 14 Jan 2022Funding: BOF - Doctoral projects
- Next Generation Screening in Quantitative Biology & Drug DiscoveryFrom15 Jul 2016 → 31 Dec 2019Funding: Department Coordination
- High resolution tandem mass spectrometer for advanced proteomicsFrom1 May 2016 → 30 Apr 2020Funding: FWO Medium Size Research Infrastructure
- Targeted aggregation as a novel healthcare applicationFrom1 Oct 2015 → 31 Dec 2020Funding: FWO Strategic Basic Research Grant
- Targeted aggregation of malignant proteomes as a novel therapeutic strategy in cancerFrom24 Sep 2015 → 21 Jun 2023Funding: FWO Strategic Basic Research Grant
- The impact of wide-spread protein aggregation in cancer.From1 Jan 2015 → 31 Dec 2018Funding: FWO research project (including WEAVE projects)
- The role of aggregation gatekeepers in proteostasis.From10 Dec 2014 → 23 Jun 2020Funding: IWT personal funding - strategic basic research grants
- Adapting targeted protein aggregation for detection.From1 Oct 2014 → 30 Sep 2018Funding: IOF - Industrial Research Fund
- Identifying novel aggregation-associated disease mutants.From1 Jan 2014 → 31 Dec 2014Funding: BOF - Other initiatives
Publications
1 - 10 of 156
- Integrating physics in deep learning algorithms: a force field as a PyTorch module.(2024)
Authors: Gabriele Orlando, Joost Schymkowitz, Frederic Rousseau
Pages: btae160 - Local structural preferences in shaping tau amyloid polymorphism(2024)
Authors: Grigoria Tsaka, Rodrigo Gallardo, Dietmar Thal, Frederic Rousseau, Joost Schymkowitz
- N-glycosylation as a eukaryotic protective mechanism against protein aggregation.(2024)
Authors: Bert Houben, Matthias De Vleeschouwer, Matthew Wilson, Gert Matthijs, Joost Schymkowitz, Frederic Rousseau
Pages: eadk8173 - Modulation of hen egg white protein techno-functionality by amyloid formation(2024)
Authors: Anja Vananroye, Paula Moldenaers, Joost Schymkowitz, Frederic Rousseau, Jan Delcour
- LRRC37B is a human modifier of voltage-gated sodium channels and axon excitability in cortical neurons(2023)
Authors: Sofie Beckers, Katerina Konstantoulea, Maarten Dewilde, Frederic Rousseau, Joost Schymkowitz, Tom Theys, Joris de Wit, Pierre Vanderhaeghen
- Mechanisms and pathology of protein misfolding and aggregation(2023)
Authors: Nikolaos Louros, Joost Schymkowitz, Frederic Rousseau
Pages: 912 - 933 - Improved coalescence and creaming stability of structured oil-in-water emulsions and emulsion gels containing ovalbumin amyloid-like fibrils produced by heat and enzymatic treatments(2023)
Authors: Frederic Rousseau, Joost Schymkowitz, Jan Delcour
- TDP‑43 pathology is associated with increased tau burdens and seeding(2023)
Authors: Sandra Oliveira Tomé, Grigoria Tsaka, Klara Gawor, Philip Van Damme, Ludo Van Den Bosch, Rik Vandenberghe, Frederic Rousseau, Joost Schymkowitz, Dietmar Thal
- Exploiting the aggregation propensity of beta-lactamases to design inhibitors that induce enzyme misfolding(2023)
Authors: Laleh Khodaparast, Ladan Khodaparast, Emiel Michiels, Rodrigo Gallardo, Bert Houben, Matthias De Vleeschouwer, Frederic Rousseau, Joost Schymkowitz
- Amyloid-like p53 as prognostic biomarker in serous ovarian cancer-a study of the OVCAD consortium(2023)
Authors: Ignace Vergote, Toon Van Gorp, Frederic Rousseau, Joost Schymkowitz
Pages: 2473 - 2484
Patents
1 - 10 of 10
- Molecules targeting ras protein (Inventor)
- Molecules targeting proteins (Inventor)
- Molecules targeting mutant ras protein (Inventor)
- Beta-lactamase inhibitors (Inventor)
- Carbon dioxide generation (Inventor)
- Molecules targeting mutant ras protein (Inventor)
- Means and methods for the prediction of amyloid core sequences (Inventor)
- Molecules targeting proteins (Inventor)
- Molecules targeting ras protein (Inventor)
- Carbon dioxide generation (Inventor)